ArticleBMC gastroenterology2016
Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.
Article in BMC gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time?World journal of transplantation · 2024Review
- Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Article
- Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation.JAMA network open · 2020Article
- Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities.Current heart failure reports · 2020Review
- Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019Review
- Impact of psychosocial comorbidities on clinical outcomes after liver transplantation: Stratification of a high-risk population.World journal of hepatology · 2019Article
- Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients.Digestive diseases and sciences · 2019Review
- Hepatitis C Virus-Viremic Liver Transplantation.Gastroenterology & hepatology · 2018Article
- Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.Current infectious disease reports · 2018Review
- Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.PloS one · 2018Article
- Use of Hepatitis C-Positive Deceased Liver Donors in Response to the Organ Shortage in an Endemic Area.Annals of transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of HCV-positive livers for HCV-positive recipients is becoming more common. Our aim is to evaluate long-term outcomes in liver transplant recipients transplanted with HCV antibody-positive organs.
methodsFrom the Scientific Registry of Transplant Recipients (1995-2013), we selected all adult liver transplant recipients with HCV, and cross-sectionally compared long-term graft loss and mortality rates between those who were transplanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative donors.
resultsWe included 33,668 HCV+ liver transplant recipients (54.0 ± 7.7 years old, 74.1% male, 71.0% white, 23.6% with liver malignancy). Of those, 5.7% (N = 1930) were transplanted from HCV+ donors; the proportion gradually increased from 2.9% in 1995 to 9.4% in 2013. Patients who were transplanted from HCV+ positive donors were more likely to be discharged alive after transplantation (95.4% vs. 93.9%, p = 0.006), but this difference was completely accounted for by a greater proportion of HCV+ donors in more recent study years (p = 0.10 after adjustment for the transplant year). After transplantation, both mortality in HCV patients transplanted from HCV+ donors (12.5% in 1 year, 24.2% in 3 years, 33.0% in 5 years) and the graft loss rate (2.2% in 1 year, 4.8% in 3 years, 7.5% in 5 years) were similar to those in HCV patients transplanted from HCV-negative donors (all p > 0.05).
conclusionsOver the past two decades, the use of HCV+ organs for liver transplantation has tripled. Despite this, the long-term outcomes of HCV+ liver transplant recipients transplanted from HCV+ donors were not different from those who were transplanted with HCV-negative organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.